Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Aug;33(8):522-30.
doi: 10.1089/dna.2013.2263. Epub 2014 Apr 10.

Correlations of MCP-1 -2518A>G polymorphism and serum levels with cerebral infarction risk: a meta-analysis

Hong-Hua Gao  1 , Lian-Bo Gao, Jia-Mei Wen
Affiliations
Meta-Analysis

Correlations of MCP-1 -2518A>G polymorphism and serum levels with cerebral infarction risk: a meta-analysis

Hong-Hua Gao et al. DNA Cell Biol. 2014 Aug.

Erratum in

Abstract

This meta-analysis was performed to evaluate the relationships between the monocyte chemoattractant protein-1 (MCP-1) -2518A>G (rs1024611 A>G) polymorphism and its serum levels, and the risk of cerebral infarction. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before October 1st, 2013 without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) or standardized mean difference (SMD) with their 95% confidence intervals (95% CIs) were calculated. Twelve case-control studies that met all the inclusion criteria were included in this meta-analysis. A total of 1272 patients with cerebral infarction and 1210 healthy control subjects were involved in this meta-analysis. Our meta-analysis results reveal that the MCP-1 -2518A>G polymorphism might increase the risk of cerebral infarction (A allele vs. G allele: OR=1.37, 95% CI: 1.18-1.60, p<0.001; GA+AA vs. GG: OR=1.33, 95% CI: 1.09-1.62, p=0.005; respectively). Furthermore, cerebral infarction patients had higher levels of serum MCP-1 than did healthy control subjects (SMD=2.96, 95% CI: 2.00-3.92, p<0.001). Statistical analysis revealed no evidence of publication bias in this meta-analysis (all p>0.05). Our findings indicate that the MCP-1 -2518A>G polymorphism and serum MCP-1 levels may contribute to the development of cerebral infarction. Thus, the MCP-1 -2518A>G polymorphism and serum MCP-1 levels could be potential biomarkers for the early detection of cerebral infarction.

PubMed Disclaimer

Figures

<b>FIG. 1.</b>
FIG. 1.
Flowchart of literature search and study selection. Twelve case–control studies were included in this meta-analysis.
<b>FIG. 2.</b>
FIG. 2.
The distribution of the number of topic-related literature in electronic databases over the last decade.
<b>FIG. 3.</b>
FIG. 3.
Subgroup analyses of the relationships between the monocyte chemoattractant protein-1 (MCP-1) −2518A>G polymorphism and cerebral infarction risk under the allele and dominant models.
<b>FIG. 4.</b>
FIG. 4.
Subgroup analyses of the relationships between serum MCP-1 levels and cerebral infarction risk.
<b>FIG. 5.</b>
FIG. 5.
Sensitivity analysis of the summary of odds ratio (OR) coefficients on the relationships between the MCP-1 −2518A>G polymorphism and serum MCP- levels, and the risk of cerebral infarction. Results were computed by omitting each study in turn. Meta-analysis random-effects estimates (exponential form) were used. The two ends of the dotted lines represent the 95% confidence interval.
<b>FIG. 6.</b>
FIG. 6.
Begger's funnel plot of publication biases on the relationships of MCP-1 −2518A>G polymorphism and serum MCP levels with the risk of cerebral infarction. Each point represents a separate study for the indicated association. Log [OR], natural logarithm of OR. Horizontal line, mean magnitude of the effect.
See this image and copyright information in PMC

References

    1. Arakelyan A., Petrkova J., Hermanova Z., Boyajyan A., Lukl J., and Petrek M. (2005). Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm 2005,175–179 - PMC - PubMed
    1. Bose S., and Cho J. (2013). Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch Pharm Res 36,1039–1050 - PubMed
    1. Buraczynska K., Luchowski P., Wojczal J., Ksiazek A., and Stelmasiak Z. (2010). Monocyte chemoattractant protein (MCP-1) A-2518G gene polymorphism in stroke patients with different comorbidities. Clin Biochem 43,1421–1426 - PubMed
    1. Chen S.Y., Zhang Z.J., Wu X.L., Wang Z.Q., Wang W., and Yang Q.D. (2007). Study the relationship between the monocyte chemoattractant protein-1 gene-2518G/A polymorphism and cerebral infarction of Han population in Chinese Hunan district. J Clin Neurol 3,167–169
    1. Dai Y.M., Guan G.Y., Han H., Zhao Q.J., Su Z.Q., and Zhang L.M. (2006). Analysis of the MCP-1 promoter-2518A/G gene polymorphism in cerebral infarction patients. J Apoplexy Nerv Dis 2,152–154

Publication types

LinkOut - more resources